Operational Updates and Recent Highlights
During Q3 2022 we: Continued the transition from COVID to cancer testing, diagnosis and treatment, with COVID contributing marginal revenue during the Quarter.
Focused strongly on large employers, insurers and re-insurers, and clinics and healthcare systems with respect to early cancer screening, leveraging our previous COVID contacts.
Initiated early cancer screening programs with large employers and are reporting results, with follow up.
Are collaborating with the Health and Safety Committees of multiple Fire Fighter stations, across many jurisdictions in
Individual, independent, Fire Fighter screening has commenced.
Initiated discussions with Fire Fighters in other Provinces in
Expanding CareOncology programs to clinic and healthcare groups for referral. Data publication a key endpoint.
Expansion into the 750 million population EU a key focus
About
The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle, as well as additional cancer diagnostics (ColonSentry, BreastSentry, and the Prostate Health Index) are processed at the Company's clinical laboratory,
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as 'expects', 'will' and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Contact:
Tel: 1-855-420-7140
Email: rgreco@stagezerols.com
(C) 2022 Electronic News Publishing, source